Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA H1047X Bortezomib + Temsirolimus + Topotecan small intestine adenocarcinoma predicted - resistant detail...
NTRK1 fusion Larotrectinib small intestine adenocarcinoma sensitive detail...
NTRK2 fusion Larotrectinib small intestine adenocarcinoma sensitive detail...
MLH1 mutant N/A small intestine adenocarcinoma not applicable detail...
MSH6 mutant N/A small intestine adenocarcinoma not applicable detail...
APC mutant N/A small intestine adenocarcinoma not applicable detail...
MLH1 negative Pembrolizumab small intestine adenocarcinoma sensitive detail...
MSH6 negative Pembrolizumab small intestine adenocarcinoma sensitive detail...
MSH6 negative Nivolumab small intestine adenocarcinoma sensitive detail...
MLH1 negative Nivolumab small intestine adenocarcinoma sensitive detail...
MLH1 negative Ipilimumab + Nivolumab small intestine adenocarcinoma sensitive detail...
MSH6 negative Ipilimumab + Nivolumab small intestine adenocarcinoma sensitive detail...
MLH1 negative Dostarlimab-gxly small intestine adenocarcinoma sensitive detail...
MSH6 negative Dostarlimab-gxly small intestine adenocarcinoma sensitive detail...
NTRK1 fusion Entrectinib small intestine adenocarcinoma sensitive detail...
NTRK2 fusion Entrectinib small intestine adenocarcinoma sensitive detail...
RET fusion Selpercatinib small intestine adenocarcinoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib small intestine adenocarcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01202409 Phase II Panitumumab CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed USA 0
NCT01208103 Phase II Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed USA 0
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Completed USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUT 5
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT03000179 Phase II Avelumab Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma Terminated USA 0
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Completed USA 0
NCT03108131 Phase II Atezolizumab + Cobimetinib Cobimetinib and Atezolizumab in Advanced Rare Tumors Completed USA 0
NCT04491955 Phase II Bintrafusp alfa + CV301 + NHS-IL12 + Nogapendekin alfa inbakicept Bintrafusp alfa + CV301 + Nogapendekin alfa inbakicept Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers Active, not recruiting USA 0
NCT04729322 Phase I Fecal microbiota + Nivolumab Fecal microbiota + Pembrolizumab Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders Active, not recruiting USA 0
NCT06333314 Phase II Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) Not yet recruiting FRA 0